BMND.NEO Biomind Labs Inc

Healthcare Biotechnology NEO Exchange
0.6900 CAD
Close of Oct 13, 2026
0.0100 0.8000
Market cap
CAD 53.5M
P/E
-
P/B
129.78x
ROE
-
Dividend yield
-
Fundamental score
0.2/5

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is BMND.NEO undervalued?

Graham number

The Graham number of Biomind Labs Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Biomind Labs Inc fundamental analysis

1 of 21 checks passed

ROE 0/2

ROE cannot be calculated: equity is negative or not reported.

ROA 0/1

Return on assets (-4,494,788.6%) is below the industry median (-19.8%).

Profit Consistency 0/2

Not profitable for at least 3 consecutive years.

Earnings Growth 5Y 0/1

Earnings per share history is shorter than 5 years.

Earnings Acceleration 0/1

Not enough positive earnings history to compare last year's growth with the 5-year average.

Earnings Growth vs Industry 0/1

Last year's EPS growth (-226.3%) is below the industry median (3.8%).

Revenue Growth 0/2

Revenue did not grow over the past 3 years or is not reported.

Short-term Liquidity 0/1

Current assets do not cover short-term liabilities.

Long-term Liabilities 1/1

Current assets cover long-term liabilities.

Debt to Equity 0/2

Debt to equity cannot be calculated: debt is not reported or equity is negative.

Debt Trend 0/1

Debt to equity has risen over the past 5 years.

Cash Runway 0/2

Cash covers 0.0 years of the current cash burn.

PE vs Market 0/1

PE is negative or not available.

PE vs Industry 0/1

PE is negative or not available.

PBV 0/1

Price to book (129.8x) is above the industry median (3.1x).

Graham Number 0/1

Graham number needs positive earnings and book value.

PEG 0/1

PEG needs positive PE and positive 5-year earnings growth.

Dividend Yield 0/2

No dividend paid in the last reported year.

Dividend Stability 0/2

Dividends were not paid steadily for the past 5 years.

Dividend Growth 0/1

Dividends paid did not grow over the past 5 years.

Payout Ratio 0/1

No dividend, or no profit to pay it from.

Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score

Biomind Labs Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Biomind Labs Inc

Biomind Labs Inc., a biotech research and development company, focuses on developing novel pharmaceutical drugs and nanotech delivery systems for various psychiatric and neurological conditions. The company is developing BMND01, which is in Phase II clinical trials for use in the treatment of depression; BMND08, a 5-Metoxi-N,N-dimethyltryptamine sublingual formulation that is in Phase II clinical trials for treatment of depression and anxiety in patients with Alzheimer's dis…

Full company profile